🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million new cases each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have shared optimism. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is viewed as essential to reduce the burden of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.